In addition to altering proliferation and symmetrical division to promote differentiation, reduction in Flii may further reduce tumor progression, whereby the exclusive nuclear SOX9 expression may increase the degradation of stabilized β-catenin. The gene discussed is FLII; the disease is neoplasm.